Sophie Wilson
In the pharmaceutical industry, licensing agreements are the backbone of innovation, commercialization, and strategic growth. These contracts allow companies to share intellectual property (IP), expand market reach, and accelerate drug development. But beneath the surface of these highstakes deals lie critical clauses that determine the success—or failure—of the partnership. This article explores the key components of pharma licensing agreements and how they shape the dynamics between licensors and licensees.
